Physician profile
Chase Kwon
NPI 1801384029
$17,644.65
in general payments reported to CMS, 2019-2025
33 companies · $11K in 2025
The $11K reported for 2025 was more than what 92% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,789 · 2023: $2,444 · 2024: $2,333 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,426 · Consulting Fee: $6,598 · Travel and Lodging: $434 · Education: $398.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,425.74 |
| Consulting Fee | $6,597.91 |
| Travel and Lodging | $433.61 |
| Education | $397.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $7,988.56 | 2022-2025 | |
| Janssen Biotech, INC. | $1,174.90 | 2022-2025 | Tremfya, Simponi, Stelara |
| Regeneron Healthcare Solutions, INC. | $980.12 | 2022-2025 | Dupixent, Libtayo |
| Incyte Corporation | $833.57 | 2022-2025 | Opzelura |
| Abbvie INC. | $815.55 | 2022-2025 | |
| Galderma Laboratories, L.P. | $655.72 | 2022-2025 | Nemluvio, Oracea, Epsolay |
| Lilly USA, LLC | $631.68 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| Ucb, INC. | $620.74 | 2023-2025 | Bimzelx, Cimzia |
| Dermavant Sciences, INC. | $584.81 | 2023-2024 | Vtama |
| Pfizer INC. | $531.66 | 2022-2025 | |
| Leo Pharma INC. | $529.95 | 2022-2025 | Anzupgo, Adbry |
| Sun Pharmaceutical Industries INC. | $432.25 | 2022-2025 | Winlevi |
| Arcutis Biotherapeutics, INC. | $420.25 | 2023-2025 | Zoryve |
| Amgen INC. | $257.38 | 2024-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $226.59 | 2022-2024 | Sotyktu |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $187.51 | 2022 | |
| Organon LLC | $165.25 | 2024-2025 | Vtama |
| Novartis Pharmaceuticals Corporation | $155.70 | 2023-2025 | |
| Revance Therapeutics, INC. | $91.75 | 2025 | Daxxify |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.03 | 2023-2024 | Spevigo, Jardiance |
| Verrica Pharmaceuticals INC. | $39.44 | 2023 | Ycanth |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $39.07 | 2024 | Siliq |
| Smith+Nephew, INC. | $31.04 | 2025 | Grafix |
| Epi Health, LLC | $30.00 | 2022 | |
| Mayne Pharma Commercial LLC | $28.53 | 2025 | |
| Krystal Biotech INC | $25.42 | 2023 | Vyjuvek |
| Renalytix Ai, INC. | $21.79 | 2024 | Kidneyintelx Blood Collection Convenience Kit |
| Medimetriks Pharmaceuticals, INC. | $19.60 | 2023 | Clindacin Etz |
| Botanix Sb INC | $19.03 | 2025 | Sofdra |
| Biofrontera INC. | $18.82 | 2025 | Ameluz |
| Almirall LLC | $18.29 | 2023 | Klisyri |
| Allergan, INC. | $15.00 | 2022 | |
| Journey Medical Corporation | $13.65 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chase Kwon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.